phil 50jili
AP Business SummaryBrief at 12:01 p.m. ESTBison football adds Omaha three-star defensive end prospect Alijah Wayne
Car Dealers Offer Promotions as Vehicle Supply Climbs
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree” or "the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis [email protected] Consolidated Balance Sheets (in thousands, except share and per share data) Consolidated Statements of Operations (in thousands, except per share data)The winter Session of Parliament will commence tomorrow and subject to exigencies of Government Business, the session is set to conclude on December 20. Parliament Winter Session: The Winter Session of Parliament is scheduled to begin on Monday in which various bills, including the Waqf Act (Amendment) Bill, will be discussed. The session will run till December 20. Other bills that are listed for introduction, consideration and passing include the Mussalman Wakf (Repeal) Bill, the Bharatiya Vayuyan Vidheyak, the Disaster Management (Amendment) Bill, the Readjustment of Representation of Scheduled Tribes in Assembly Constituencies of the State of Goa Bill, the Bills of Lading Bill, the Carriage of Goods by Sea Bill, the Railways (Amendment) Bill, the Banking Laws (Amendment) Bill, and the Oilfields (Regulation and Development) Amendment Bill. The Boilers Bill, the Rashtriya Sahkari Vishwavidyalaya Bill, the Punjab Courts (Amendment) Bill, the Merchant Shipping Bill, the Coastal Shipping Bill, and the Indian Ports Bill, are also included in the list. The winter Session of Parliament will commence tomorrow and subject to exigencies of Government Business, the session is set to conclude on December 20. There will be no sitting of Lok Sabha and Rajya Sabha on November 26, to commemorate "Constitution Day" as per a statement. Meanwhile, ahead of the commencement of the Winter Session of Parliament on Monday, floor leaders of INDIA bloc parites will hold a meeting in Parliament House to decide the strategy of opposition, sources said. The meeting will be held at 10 am on November 25. Congress MP and Leader of Opposition in Rajya Sabha Mallikarjun Kharge is expected to decide the strategy of the Opposition for the Parliamentary Session, they said. Notably, Congress is expected to raise the Manipur issue and bribery charges against the Adani Group. Earlier in the day, Parliamentary Affairs Minister Kiren Rijiju asserted that the union government is "ready to discuss any topic" while calling for a peaceful session of Parliament. Speaking to reporters on Sunday after the all-party meeting in Delhi, Rijiju said several topics were raised requesting for discussion in Parliament as winter session is scheduled to kick off tomorrow. "A total of 42 leaders from 30 political parties were present in the meeting. There are many topics. Everyone has asked for discussion on some topics but we want that there should be a good discussion in the Lok Sabha and Rajya Sabha. The government is ready to discuss any topic. Our only request is that the House should run well and there should be no ruckus. Every member wants to participate in the discussion but the House should run well. To run the winter session well, everyone's cooperation is needed and everyone's participation is necessary," Kiren Rijiju said. The all-party meeting was attended by all floor leaders of political parties in both the houses of the Parliament. The all-party meeting in the national capital began at 11 am in the Main Committee Room, at Parliament House Annexe in the national capital. The meeting was presided over by Defence Minister Rajnath Singh. Congress MPs Jairam Ramesh, Pramod Tiwari and K Suresh along with JD(U) MP Upendra Kushwaha and other leaders joined the meeting. PV Midhun Reddy (YSRCP), V Vijaysai Reddy (YSRCP), Sasmit Patra (BJD), Vaiko (MDMK), Ramgopal Yadav (SP), K Suresh (Congress), Lavu Sri Krishna Devarayalu (TDP) were also present. Stay informed on all the latest news , real-time breaking news updates, and follow all the important headlines in india news and world News on Zee News.
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical DevelopmentTexans star to have MRI on injury | Sporting News
Realty firm Signature Global Ltd plans to launch multiple housing projects worth Rs 50,000 crore in Delhi-NCR over the next three years as part of its expansion plan amid strong consumer demand. Signature Global, listed on stock exchanges, is one of the leading real estate firms in the country. It sold properties worth Rs 7,200 crore last fiscal and is targeting to sell Rs 10,000 crore this fiscal. In an interview with PTI, Signature Global Chairman Pradeep Aggarwal noted that housing demand continues to be strong in Gurugram, and the company would keep expanding its presence by launching more projects and acquiring new land parcels. "We have a strong launch pipeline. We are targeting to launch projects worth Rs 50,000 crore over the next three years," he said. The company has already acquired land in Gurugram and adjoining areas to launch multiple projects, Aggarwal noted. "We gave guidance to launch Rs 16,000 crore worth of projects during the current fiscal year. We achieved Rs 9,000 crore launch in the first half of this fiscal and around Rs 5,000 crore worth of properties have been launched in the current quarter," Aggarwal said. He said the launch guidance would be achieved easily. On pre-sales guidance, Aggarwal said, "We had given a pre-sales (sales bookings) guidance of Rs 10,000 crore for the current fiscal. We were among few listed real estate developers to set such a big target". He highlighted that the company has already achieved sales bookings worth Rs 5,900 crore in the first half of this fiscal. Considering the strong performance in the first six months, he said, "We are quite hopeful of over-achieving of our annual guidance". Signature Global's sale bookings jumped over three times to Rs 5,900 crore in the April-September period of 2024-25 from Rs 1,860 crore a year ago. Signature Global, which has a significant presence in the Gurugram market, clocked sale bookings of Rs 7,270 crore in 2023-24. Aggarwal said the company keeps evaluating proposals to buy land in the Gurugram market and is also exploring to enter Noida, Greater Noida and Yamuna Expressway property markets. Earlier this month, the company reported a consolidated net profit of Rs 4.15 crore for the quarter ended September. The company had posted a net loss of Rs 19.92 crore in the year-ago period. Its total income rose to Rs 777.42 crore in the second quarter of this fiscal from Rs 121.16 crore in the year-ago period. Signature Global has so far delivered 11 million square feet of housing area. It has a pipeline of about 32.2 million square feet of saleable area in forthcoming projects, along with 16.4 million square feet of ongoing projects. Get Latest News Live on Times Now along with Breaking News and Top Headlines from Real Estate, Business Economy and around the world.
Push to salvage climate talks after poor nations bristle at cashGlobal Enterprise Financial Management Software Market Size, Share and Forecast By Key Players-Epicor, infor, Microsoft Corporation, Oracle, FreshbooksA Muslim man accused of shooting a Jewish man and firing at police officers in Chicago last month had researched the locations of synagogues and Jewish schools in the days leading up to the attack, prosecutors said during a detention hearing Friday. Sidi Mohamed Abdallahi, 22, an undocumented immigrant from Mauritania, allegedly used his phone to identify potential targets in the West Rogers Park neighborhood before the October 26 shooting. Among the addresses found on his phone was Ezrat Israel, a synagogue located one block from the shooting site. 1 View gallery Sidi Mohamed Abdallahi Jewish man shot en route to a synagogue in Chicago ( Video: Social Media ) “This was not anything but a planned attack ... an attempted assassination of these people,” Assistant State’s Attorney Anne McCord Rodgers according to The Yeshiva World. “This was a calculated plan, on a public street... and an attempted slaughter of that person and law enforcement officers.” Get the Ynetnews app on your smartphone: Google Play : https://bit.ly/4eJ37pE | Apple App Store : https://bit.ly/3ZL7iNv Abdallahi, who had been living in the U.S. for at least two years and working at an Amazon warehouse, appeared in court after recovering from gunshot wounds sustained in a shootout with police. Judge Susana Ortiz ordered him held without bail on charges of attempted murder, hate crimes and terrorism. Investigators said data recovered from Abdallahi’s phone revealed antisemitic motives and extensive planning. He had marked the locations of synagogues, conducted online searches for “Jewish community center” and “gun store,” and stored over 100 antisemitic and pro-Hamas images and videos. >
A frustrated Leicester City boss Steve Cooper confirmed he will write to the PGMOL after his side's 2-1 loss to Chelsea. Cooper also bit his tongue when discussing referee Andy Madley's performance to avoid getting into further trouble. The Foxes boss was adamant his side should have had a penalty in the second half when Chelsea defender Levi Colwill looked to have brought down Stephy Mavididi . However, Madley did not award it and VAR opted not to intervene. Leicester did have a penalty in second half stoppage time when Bobby De Cordova-Reid was fouled by Romeo Lavia , although it took a VAR review to get there. Leigh Doughty, who began the game as fourth official but took over linesman duties from Mark Scholes at half-time after the latter picked up an injury , initially flagged Reid to be offside. But replays showed the Leicester forward was clearly onside as Madley was told to award a penalty. Speaking to talkSPORT's Sam Matterface after the contest, Cooper, who was booked by Madley for his protests in the second half, conceded he felt the club had to take extreme measures to get the PGMOL's attention after the official's performance. "I think the club needs to, and they will, they will to be fair because I'm not saying that we're not, but in this moment we have got to officially write things or pick up the phone and go, 'Come on, what's going on here,'" Cooper told talkSPORT. "The last thing the PGMOL needed this week is things like that. It's no good for anybody. "Sometimes, they can go for you and against you. But it's the last thing they need in the first Premier League game after the international break. "Everybody is talking more about the decisions than the actual game, which is always a good indicator of how the game's been refereed. Cooper added: "We had him (Madley) at Palace as well for the VAR. "I won't say anything that's going to get me into trouble. But we've had some bad luck with him this year. That's all I'll say on it." Madley was indeed the VAR when Leicester and Crystal Palace met in the fourth game of the Premier League season. Palace striker Jean-Philippe Mateta scored a 92nd-minute equaliser from the spot to rescue his side from 2-0 down as the contest ended 2-2. However, Cooper was left furious over Mateta's first goal as it was initially flagged for offside, only for VAR to overturn the decision and award it. But Cooper believed VAR had used the wrong freeze-frame to decide whether Mateta was off-side as images shared on social media proved the Foxes boss was right to be angry. Leicester met with the PGMOL two days after but it was explained to them no human error was made and the correct frame was used to decide whether Mateta was off-side or not. However, Cooper held nothing back during his press conference in the days after. "We're over it now, it was an awful human error that we believe has been hidden a little bit," Cooper said. "We have seen different images that show he clearly was offside, but unfortunately they froze it at the wrong time and he was deemed to be onside. Everything that has been seen has been a false image. "On Monday we showed the Premier League with clear footage that actually the game was stopped at the wrong time. "Decisions go against you whether it's in-game or VAR and we've had a massive error go against us. We don't want it to go under the radar because I don't think that's right for the players or for the supporters. "Errors like that shouldn't happen and it's why we're changing to the semi-automated system. We felt very let down by it. We needed to stand up for the club and tell the Premier League what we thought."President Bola Tinubu on Sunday urged leaders in West Africa to draw inspiration from Ghana’s recent peaceful elections as a model of democratic maturity and commitment to national unity. Tinubu said this at the opening of the 66th Ordinary Session of ECOWAS at the State House Conference Centre, Abuja. He lauded President Nana Akufo-Addo and the people of Ghana for the resounding success of their recent presidential and parliamentary elections, setting a high standard for the region. The President stated, “I urge all of us in the region to learn from this good democratic practice and prioritise our country’s national unity to ensure political stability of the region so that this manner of peaceful transition becomes the culture of democracy not only in West Africa but also in the entire Africa continent.” Tinubu explained further, “Despite the challenges of interrupted democratic governance in some West African countries, the region has continued to record democratic gains. “Just a week ago, on December 7, 2024, Presidential and Parliamentary elections took place in Ghana, the second-largest democracy in our region. “One of the leading candidates who happens to be the incumbent Vice President, Mahamudu Bawumia, together with the leadership of the ruling party, New Patriotic Party, conceded defeat and accepted the outcome of the Presidential election by congratulating the President-elect, John Dramani Mahama of National Democratic Congress for his victory, even before the official announcement of the election results.” He opined that this gesture, as it happened in Nigeria in 2015, demonstrates political maturity and respect for the will of the people of Ghana. Tinubu praised President Akufo-Addo for his exceptional leadership and unwavering commitment to ECOWAS during his two-year term, describing him as a formidable Pan-Africanist. He also congratulated the government and people of Senegal on their successful parliamentary elections. The Nigerian leader praised Ghana’s Foreign Minister, Shirley Ayokor Botchwey, for painstakingly leading the ECOWAS Ministerial Committee of the Reform. He wished her a successful tenure in her new role as the Secretary-General of the Commonwealth. In his second term as ECOWAS Chair, President Tinubu highlighted achievements from his first term, including strides in regional integration, economic growth, conflict resolution, and counterterrorism efforts. He said the ECOWAS Trade Liberalisation Scheme and Common External Tariff have strengthened trade and economic cooperation. Related News Caution Shettima over Kemi Badenoch attack, Igboho urges Tinubu Grid failures national embarrassment, says APC chieftain Tinubu hosts ECOWAS presidents for 66th Ordinary Session at Aso Rock Villa “Similarly, regional infrastructure projects such as the West African Gas Pipeline, the West Africa Power Pool, and modernising key border posts with advanced equipment and joint border operations utilising state-of-the-art technology have significantly enhanced connectivity and promoted greater regional integration. “Furthermore, our efforts in stabilising our region through peacekeeping missions currently in the Gambia and Guinea Bissau, as well as previous operations in Liberia and Sierra Leone, have demonstrated our capacity to act decisively in the face of adversity,” he opined. President Tinubu said the ECOWAS Regional Action Plan on the Fight Against Terrorism has provided a comprehensive framework to combat violent extremism and enhance regional security. As ECOWAS nears its 50th anniversary in 2025, the Authority’s Chairman urged member states to recommit to the bloc’s founding ideals of economic integration, peace, and prosperity. “As a regional community, we must maintain our fundamental responsibility: to protect our citizens and create an enabling environment where they can prosper. “As leaders, we know that security is not a luxury but a necessity. “Equally, enhancing the living standards of our people is not an aspiration but an obligation,” he said. The Presidents of Cote d’Ivoire, Ghana, The Gambia, Guinea Bissau, Liberia, and Senegal attended in person alongside the Vice President of Sierra Leone, the Finance Minister of the Benin Republic, the Minister of Foreign Affairs of Togo, and the Ambassador of Cape Verde to Nigeria. The President of the ECOWAS Commission, Dr Omar Touray, commended Nigeria for paying 100 per cent of its community levy for 2023 and substantial remittances for 2024, reflecting Nigeria’s leadership and commitment under President Tinubu. “For the first time in 19 years, Nigeria has paid 100% of its community levy from 2023. “I’m therefore pleased to announce that on Friday, December 13, 2024, Nigeria paid N85 billion and $54 million, representing 100% of the 2023 levy and the 2024 levy up to July 2024. “We all agree that this payment underscores the leadership and commitment of President Tinubu, the government and the people of Nigeria to our community. At a more personal level, it represents confidence in the management I have been privileged to lead since 2022,” said Touray. He encouraged other member states to meet their financial commitments diligently.The record will show that tight end Trey McBride had a great season, Marvin Harrison Jr. has a promising future, the Cardinals' defense played over its head for much of the year and Arizona was almost a good football team in 2024. Key word — almost. A frustrating stretch continued on Saturday when the Cardinals (7-9) lost 13-9 to the host Los Angeles Rams. Arizona was pushing for a go-ahead touchdown in the final minute, but Kyler Murray's pass took an unlucky bounce off McBride's helmet and LA's Ahkello Witherspoon made a spectacular grab for the interception, snagging the ball just before it hit the turf. “I think we can compete with anybody, but again, that doesn’t count,” second-year coach Jonathan Gannon said. “It’s about winning and losing, you what I mean? I just got to do a better job, but I know they’re doing the right things.” The Cardinals did a lot of things right against the Rams. Despite being eliminated from the postseason, Arizona competed hard. Murray completed 33 of 48 passes for 321 yards and a touchdown — but also had two interceptions. McBride caught 12 passes for 123 yards, including his first TD catch of the year. Harrison had one of his best games with six catches for 96 yards. “I’m going to choose to be positive about it,” Murray said. “I see a light at the end of that tunnel. I think we’re a couple plays away, a couple of plays away from being a 10-win team or right where we want to be, going to the playoffs or winning the division.” Arizona Cardinals quarterback Kyler Murray loses his helmet on a play in the end zone during the first half of an NFL football game against the Los Angeles Rams, Saturday, Dec. 28, 2024, in Inglewood, Calif. Credit: AP/Alex Gallardo The Cardinals' defense played well for most of the game, limiting the Rams to 257 yards. But in the end, it was another loss. The Cardinals have dropped five of six after starting 6-4. “I know we’re close, man, and I know it’s hard to see that,” Gannon said. “For me, that’s hard to take on the chin but we’ll get better from it. We’ll get better.” What’s working The Murray-to-Harrison connection was much better on Saturday, producing several big plays. Gannon challenged Harrison to be more physical against opposing defensive backs last week, and the receiver responded, looking much more like the player the Cardinals expected when they selected him with the No. 4 overall pick. Arizona Cardinals head coach Jonathan Gannon answers question after an NFL football game against the Los Angeles Rams, Saturday, Dec. 28, 2024, in Inglewood, Calif. Credit: AP/Alex Gallardo “I think the physicality of it, coming from college to the league, guys don’t realize how physical you can be when you get to the league,” Murray said. “He's going to be big time.” What needs help After doing a great job of taking care of the ball over the first 11 games, Murray has thrown seven interceptions over the past five. A few of those came in late-game situations when he had to take a chance and force a pass, but it's still not a good trend. Stock up McBride had his third 100-yard game of the season, showing sure hands and fighting through contact for extra yards. The third-year player has 1,081 yards receiving this season, becoming just the second tight end in franchise history to exceed 1,000 yards. The other was Hall of Famer Jackie Smith, who had 1,205 yards in 1967. He has 104 catches and is just the 10th tight end in NFL history to top 100 in a season. Stock down Arizona's special teams have been very good for most of the year, but Los Angeles' block of an extra point attempt by Chad Ryland in the third quarter proved costly. If the Cardinals had trailed by three points on the final drive instead of four, they would have had the option of kicking a tying field goal in the final minute. Injuries RB James Conner tried to battle through a knee injury against the Rams, but gained just 4 yards on the ground. His status for the season's final game is uncertain. LB Joey Blount (ribs) and CB Elijah Jones (ankle) were inactive. Key number 822 — Harrison's receiving yards on the season. That ranks third for a rookie in franchise history behind Anquan Boldin (1,377 in 2003) and Frank Sanders (883 in 1995). Next steps Arizona's final game will be at home on Sunday against the San Francisco 49ers, who are also eliminated from the playoff race.
Kane hat trick against Augsburg hides Bayern’s concerning lack of goalsThe people that president-elect Donald Trump has selected to lead federal health agencies in his second administration include a retired congressman, a surgeon and a former talk-show host. All of them could play pivotal roles in fulfilling a new political agenda that could change how the government goes about safeguarding Americans' health — from health care and medicines to food safety and science research. And if Congress approves, at the helm of the team as Department of Health and Human Services secretary will be prominent environmental lawyer and anti-vaccine organizer Robert F. Kennedy Jr. By and large, the nominees don't have experience running large bureaucratic agencies, but they know how to talk about health on TV . Centers for Medicare and Medicaid pick Dr. Mehmet Oz hosted a talk show for 13 years and is a well-known wellness and lifestyle influencer. The pick for the Food and Drug Administration, Dr. Marty Makary, and for surgeon general, Dr. Janette Nesheiwat, are frequent Fox News contributors. Many on the list were critical of COVID-19 measures like masking and booster vaccinations for young people. Some of them have ties to Florida like many of Trump's other Cabinet nominees: CDC pick Dr. Dave Weldon represented the state in Congress for 14 years and is affiliated with a medical group on the state's Atlantic coast. Nesheiwat's brother-in-law is Rep. Mike Waltz , R-Fla., tapped by Trump as national security adviser. Here's a look at the nominees' potential role in carrying out what Kennedy says is the task to “reorganize” agencies, which have an overall $1.7 billion budget; employ 80,000 scientists, researchers, doctors and other officials; and affect the lives of all Americans. The Atlanta-based CDC, with a $9.2 billion core budget, is charged with protecting Americans from disease outbreaks and other public health threats. Kennedy has long attacked vaccines and criticized the CDC, repeatedly alleging corruption at the agency. He said on a 2023 podcast that there is "no vaccine that is safe and effective,” and urged people to resist the CDC's guidelines on if and when kids should get vaccinated . Decades ago, Kennedy found common ground with Weldon , the 71-year-old nominee to run the CDC who served in the Army and worked as an internal medicine doctor before he represented a central Florida congressional district from 1995 to 2009. Starting in the early 2000s, Weldon had a prominent part in a debate about whether there was a relationship between a vaccine preservative called thimerosal and autism. He was a founding member of the Congressional Autism Caucus and tried to ban thimerosal from all vaccines. Kennedy, then a senior attorney for the Natural Resources Defense Council, believed there was a tie between thimerosal and autism and also charged that the government hid documents showing the danger. Since 2001, all vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with the exception of inactivated influenza vaccine. Meanwhile, study after study after study found no evidence that thimerosal caused autism. Weldon's congressional voting record suggests he may go along with Republican efforts to downsize the CDC, including to eliminate the National Center for Injury Prevention and Control, which works on topics like drownings, drug overdoses and shooting deaths. Weldon also voted to ban federal funding for needle-exchange programs as an approach to reduce overdoses, and the National Rifle Association gave him an “A” rating for his pro-gun rights voting record. Kennedy is extremely critical of the FDA, which has 18,000 employees and is responsible for the safety and effectiveness of prescription drugs, vaccines and other medical products — as well as overseeing cosmetics, electronic cigarettes and most foods. Makary, Trump’s pick to run the FDA, is closely aligned with Kennedy on several topics . The professor at Johns Hopkins University who is a trained surgeon and cancer specialist has decried the overprescribing of drugs, the use of pesticides on foods and the undue influence of pharmaceutical and insurance companies over doctors and government regulators. Kennedy has suggested he'll clear our “entire” FDA departments and also recently threatened to fire FDA employees for “aggressive suppression” of a host of unsubstantiated products and therapies, including stem cells, raw milk , psychedelics and discredited COVID-era treatments like ivermectin and hydroxychloroquine. Makary's contrarian views during the COVID-19 pandemic including the need for masking and giving young kids COVID vaccine boosters. But anything Makary and Kennedy might want to do when it comes to unwinding FDA regulations or revoking long-standing vaccine and drug approvals would be challenging. The agency has lengthy requirements for removing medicines from the market, which are based on federal laws passed by Congress. The agency provides health care coverage for more than 160 million people through Medicaid, Medicare and the Affordable Care Act, and also sets Medicare payment rates for hospitals, doctors and other providers. With a $1.1 trillion budget and more than 6,000 employees, Oz has a massive agency to run if confirmed — and an agency that Kennedy hasn't talked about much when it comes to his plans. While Trump tried to scrap the Affordable Care Act in his first term, Kennedy has not taken aim at it yet. But he has been critical of Medicaid and Medicare for covering expensive weight-loss drugs — though they're not widely covered by either . Trump said during his campaign that he would protect Medicare, which provides insurance for older Americans. Oz has endorsed expanding Medicare Advantage — a privately run version of Medicare that is popular but also a source of widespread fraud — in an AARP questionnaire during his failed 2022 bid for a U.S. Senate seat in Pennsylvania and in a 2020 Forbes op-ed with a former Kaiser Permanente CEO. Oz also said in a Washington Examiner op-ed with three co-writers that aging healthier and living longer could help fix the U.S. budget deficit because people would work longer and add more to the gross domestic product. Neither Trump nor Kennedy have said much about Medicaid, the insurance program for low-income Americans. Trump's first administration reshaped the program by allowing states to introduce work requirements for recipients. Kennedy doesn't appear to have said much publicly about what he'd like to see from surgeon general position, which is the nation's top doctor and oversees 6,000 U.S. Public Health Service Corps members. The surgeon general has little administrative power, but can be an influential government spokesperson on what counts as a public health danger and what to do about it — suggesting things like warning labels for products and issuing advisories. The current surgeon general, Vivek Murthy, declared gun violence as a public health crisis in June. Trump's pick, Nesheiwat, is employed as a New York City medical director with CityMD, a group of urgent care facilities in the New York and New Jersey area, and has been at City MD for 12 years. She also has appeared on Fox News and other TV shows, authored a book on the “transformative power of prayer” in her medical career and endorses a brand of vitamin supplements. She encouraged COVID-19 vaccines during the pandemic, calling them “a gift from God” in a February 2021 Fox News op-ed, as well as anti-viral pills like Paxlovid. In a 2019 Q&A with the Women in Medicine Legacy Foundation , Nesheiwat said she is a “firm believer in preventive medicine” and “can give a dissertation on hand-washing alone.” As of Saturday, Trump had not yet named his choice to lead the National Institutes of Health, which funds medical research through grants to researchers across the nation and conducts its own research. It has a $48 billion budget. Kennedy has said he'd pause drug development and infectious disease research to shift the focus to chronic diseases. He'd like to keep NIH funding from researchers with conflicts of interest, and criticized the agency in 2017 for what he said was not doing enough research into the role of vaccines in autism — an idea that has long been debunked . Associated Press writers Amanda Seitz and Matt Perrone and AP editor Erica Hunzinger contributed to this report. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
‘Living in a home that damages health the norm for far too many older people’Stock market today: Losses for Big Tech pull US indexes lower
Donald Trump has voiced his demand for clarity as perplexing drone sightings persist across the United States, leaving authorities baffled. The President-elect took to Truth Social, stating on Friday: "Mystery sightings all over the country. Can this really be happening without our government's knowledge? I don't think so! Let the public know, and now. Otherwise, shoot them down!!!" Commencing last month, most of the unusual drone sightings have been reported in New Jersey , r eports Daily Express UK. Mystery New Jersey drones could be Mexican cartel posing major safety threat Origin of mystery drones revealed by UFO expert as he warns of 'security threat' Locals have reported multiple drones nocturnally navigating the skies around important sites such as the Picatinny Arsenala crucial military research baseand Trump's own Bedminster golf course. Some local reports indicate these drones are unusually large, even SUV-sized, which surpasses typical recreational drone dimensions. Public reaction is mixed; Governor Phil Murphy assures residents that the drone activity poses no risk, while others maintain skepticism. Congressman Andy Kim raised alarm by posting a drone video taken near Round Valley Reservoir and commented: "This has gone on for weeks. It's hard to understand how, with the technology we have, we aren't able to track these devices to determine origin." In response to heightening anxieties, Homeland Security officials convened with community leaders to deliberate on the matter earlier this week. Nonetheless, Alejandro Mayorkas, the Homeland Security Secretary, has brushed off serious concerns, hinting that the reported drone incidents might simply be misidentified sightings. DON'T MISS: Mystery New Jersey drones not from Iranian 'mothership' - Pentagon Mystery New Jersey drones should be shot down, senator demands Concerns grow over mystery New Jersey drones after they evade detection Mayorkas said: "I joined local authorities last night on a mission to track down a drone hovering over New Jersey , and this is what we witnessed. We headed to Round Valley Reservoir, where an officer pointed out lights moving low above the treetops." He added: "The lights alternated between solid white and flashes of red and green." He ended with his summation: "We have not seen any unusual activity. We know of no threat. We know of no nefarious activity. Technology has not confirmed any drone sightings." Some reports, Mayorkas explained, turned out to be small aircraft rather than drones. However, with a surge in sightings nationwide - from Washington DC to California - skepticism remains high. The FBI has initiated an investigation and is urging residents to submit any evidence, such as photos or videos. Witnesses shared their encounters on social media, with one claiming to have spotted a drone near LaGuardia Airport, raising concerns about its proximity to the flight path. The Pentagon maintains that there is no threat to national security but remains unable to explain the origin or operators of the drones. As officials continue their search for answers, conspiracy theories have emerged to fill the information gap. Some theorists have linked the sightings to "Project Blue Beam," an age-old conspiracy claiming governments plan to stage celestial events or even alien invasions to manipulate public opinion. The debate and the mystery surrounding the drone sightings continue. While these ideas may seem outlandish, they have gained momentum online, driven by frustration over the absence of official explanations.Venlo, the Netherlands, Nov. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two new tools for designing and ordering custom solutions that can be used to support microbial analysis of bacterial, fungal and viral targets. These new tools enable researchers to customize their assays and panels for use on the QIAcuity digital PCR system as well as on any third-party next-generation sequencing (NGS) system. They also build on more than 700 digital PCR assays that are currently available for microbial targets through the GeneGlobe platform at https://geneglobe.qiagen.com . The new products make nanoplate digital PCR (dPCR) suitable for even more microbial targets in applications ranging from wastewater testing to food production to analysis of human pathogens. With nanoplate dPCR, rare targets in low-biomass samples with high levels of PCR inhibitors can be measured without a standard curve and with high accuracy and precision. “The demands for microbial detection, tracking and scientific research can be extremely specialized. Reliable and accurate tools that can be customized give scientists the flexibility they need to outpace pathogens and accelerate the tempo of discovery,” said Nitin Sood, Senior Vice President and head of QIAGEN’s Life Sciences Business Area. “With the launch of our design tool for Custom dPCR Microbial Assays and the new QIAseq xHXB panels, we are addressing the demands of our customers. QIAGEN will continue to expand our offering of accurate, reliable and easy-to-use solutions.” The new tools are: Design tool for Custom dPCR Microbial Assays – The first-of-its-kind custom assay design tool enables users to design primers and probes for their specific microbial targets of interest and is tailored specifically for bacterial, fungal and viral targets. The design tool software is powered by a sophisticated and thoroughly tested algorithm developed specifically for microbial applications. Researchers can benefit from a user-friendly and intuitive tool that helps them quickly obtain custom assays with optimal sensitivity, specificity and accurate off-target prediction. QIAseq xHYB Custom Microbial Panels – Customers can completely design their own NGS panels, overcoming limitations of panels offered by other vendors, which are designed against a few genomes of a given target and thereby often cause large gaps in coverage. The QIAseq xHYB Custom Microbial Panels advanced algorithm enables researchers to design their assays against many whole genomes at once, allowing them to achieve the highest possible resolution in applications such as microbial detection. QIAGEN continues to expand its portfolio dPCR assays, supporting laboratories to increase their detection capabilities and improve their results. In September, the company added over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications. These newly launched cancer and microbial assays meet the level of quality, multiplexing capabilities, customization, precision and sensitivity associated with all QIAcuity products. Customizable digital PCR assays and the customizable panels and assays are now available on QIAGEN’s GeneGlobe web portal ( https://geneglobe.qiagen.com ), which integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs and pathways. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com . Forward-Looking Statement Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Corporate
James Madison 71, Jacksonville St. 65SMITHFIELD, R.I. (AP) — Malik Grant rushed for 204 yards and three touchdowns and Rhode Island beat Bryant 35-21 on Saturday to capture its first league title in 39 years. Rhode Island (10-2, 7-1 Coastal Athletic Association) secured the program's seventh title, with each of the previous six coming in the Yankee Conference. The Rams tied a program record for total wins in a season with 10, first set in 1984 and matched in 1985. Hunter Helms threw for 209 yards with one touchdown and one interception for Rhode Island. Grant also added his first touchdown reception of the season. Grant rushed for 47 yards on the first snap of the second half. He ran for 56 yards on the drive that ended with his 4-yard touchdown catch for a 20-14 lead. An interception by Braden Price on the ensuing Bryant possession set up another Grant rushing touchdown. Bryant scored in the fourth quarter to make it a one-score game, but a 15-play, 72-yard drive ended with a 3-yard touchdown run by Grant. Grant's 13 rushing touchdowns are tied for Rhode Island's single-season record set last season by Ja’Den McKenzie. Brennan Myer threw for 189 yards with two touchdowns and two interceptions for Bryant (2-10, 0-8). Dylan Kedzior rushed for 80 yards and a touchdown, and Landon Ruggieri caught eight passes for 105 yards and a score. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football